© 2019 Peptilogics  I  All Rights Reserved

News & Updates

Peptilogics is attending the 37th Annual J.P. Morgan Healthcare Conference on January 7-10, 2019

Therapeutic Development to Address Potential Orphan Indication and Global Pandemic

Peptilogics, which develops peptide-based therapeutics with its computational  biology platform, announced today that it has been cleared by Australia’s Therapeutics Goods Administration to begin the first in-human Phase 1 study of PLG0206, which is being developed to address prosthetic joint infection (PJI) and the global pandemic of multi-drug resistant bacterial infections. The PLG0206 clinical study received ethics app...

Please reload